D.5	Dasabuvir, ombitasvir + paritaprevir + ritonavir, pegylated interferon alfa (2a & 2b) – hepatitis C virus infection – EML
Draft recommendation	☒ Recommended ☐ Not recommended Justification: Pangenotypic DAAs available and recommended Per INF - low efficacy, high toxicity
Does the proposed medicine address a relevant public health need?	☐ Yes ☐ No ☐ Not applicable Comments:
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process)	☐ Yes ☐ No ☐ Not applicable Comments:
Does adequate evidence exist for the safety/harms associated with the proposed medicine? (this may be evidence included in the application, and/or additional evidence identified during the review process)	☐ Yes ☐ No ☐ Not applicable Comments:
Are there any adverse effects of concern, or that may require special monitoring?	☐ Yes ☐ No ☐ Not applicable Comments:

Are there any special requirements for the safe, effective and appropriate use of the medicines? (e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)	☐ Yes ☐ No ☐ Not applicable Comments:
Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?	☐ Yes ☐ No ☐ Not applicable Comments:
Are there any issues regarding the registration of the medicine by national regulatory authorities? (e.g. accelerated approval, lack of regulatory approval, off-label indication)	☐ Yes ☐ No ☐ Not applicable Comments:
Is the proposed medicine recommended for use in a current WHO guideline? (refer to: https://www.who.int/publications/who-guidelines)	☐ Yes ☐ No ☐ Not applicable Comments: